TABLE 1.
Main reports on Pneumocystis pneumonia treatment using caspofungin
| Author(s) (reference), yr of publication | Patient status (no. of patients)b | Regimena | Treatment efficacy or failure |
|---|---|---|---|
| Beltz et al. (5), 2006 | ALL (1) | CAS and SMX-TMP | Efficacy |
| Zhang et al. (6), 2006 | COPD (1) | CAS and SMX-TMP | Efficacy |
| Annaloro et al. (7), 2006 | BMTR (1) | CAS and SMX-TMP | Efficacy |
| Utili et al. (8), 2007 | RTR (4) | CAS and SMX-TMP | Efficacy |
| Mu et al. (9), 2009 | CML (1) | CAS and SMX-TMP | Efficacy |
| Ceballos et al. (10), 2011 | HIV infection (1) | CAS and SMX-TMP | Efficacy |
| Armstrong-James et al. (11), 2011 | HIV infection (4) | CAS and SMX-TMP | Efficacy |
| Tu et al. (12), 2013 | RTR (3) | CAS and SMX-TMP | Efficacy |
| Lee et al. (13), 2016 | HIV (1) | CAS and SMX-TMP | Efficacy |
| Lu et al. (14), 2017 | HTR (1) | CAS and SMX-TMP | Efficacy |
| Zhang et al. (15), 2018 | Non-HIV immunosuppression (14) | CAS and SMX-TMP | Efficacy |
| Koshi et al. (16), 2019 | Sjogren’s syndrome (1) | CAS and SMX-TMP | Efficacy |
| Hof and Schnülle (18), 2008 | Wegener’s disease (1) | CAS | Efficacy |
| Lee et al. (19), 2017 | HIV infection (1) | CASc | Efficacy |
| Huang et al. (20), 2018 | Autoimmune diseases (2) | CASc | Efficacy |
| Huang et al. (21), 2019 | HIV infection (7) | CASc | Efficacy/failured |
| Kamboj et al. (22), 2006 | Cancer (2) | CAS | Failure |
| Kim et al. (23), 2013 | HIV-infection (4) | CAS | Failure |
a
CAS and SMX-TMP, caspofungin and sulfamethoxazole-trimethoprim combination; CAS, caspofungin.
b
ALL, Acute lymphoblastic leukemia; COPD, chronic obstructive pulmonary disease; RTR renal transplant recipient; CML, chronic myelomonocytic leukemia; HIV, human immunodeficiency virus; HRT, heart transplant recipient; BMTR, bone marrow transplant recipient.
c
CAS as second-line treatment.
d
Efficacy, 4 out of 7 cases.